Given that the combination of RPT and PD-1/PD-L1 inhibitors has been proposed as a potentially synergistic therapeutic strategy, we examined whether RPT influenced PD-L1 expression in tumor cells (Supplementary Figure S3). The gene discussed is CD274; the disease is neoplasm.